Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.|
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|04/16/15||IRIDEX' Total Glaucoma Solution Campaign for US Market to Debut at Annual Congress of the American Society of Cataract and Refractive Surgery|
|Solution includes IQ 532™ Laser for Repeatable MicroPulse® Laser Trabeculoplasty and the New Cyclo G6™ System with the Proprietary MicroPulse P3 Disposable
MOUNTAIN VIEW, Calif., April 16, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced the debut of its Total Glaucoma Solution, a commercial offering for the US market focused on the Company's growing portfolio of glaucoma products. The recent introduction of the Cyclo G6 system and its family of disposable probes combined... |
|03/30/15||IRIDEX Granted U.S. Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries|
|New iClip™ Closure Device Focused on Glaucoma with Broadening Applications in Other Specialties of Ophthalmology
MOUNTAIN VIEW, Calif., March 30, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced that the United States Patent and Trademark Office granted the Company a patent for a new proprietary disposable device intended to replace certain suturing techniques in eye surgery. The iClip Closure Device will initially be focused on trabeculectomies and is ... |
|03/17/15||IRIDEX Announces First Commercial Sales of New Cyclo G6™ Glaucoma Laser Systems|
|Initial Orders Include the Recently Patented MicroPulse® P3 Disposable Probe
MOUNTAIN VIEW, Calif., March 17, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable.
Glaucoma is an eye diseas... |
|03/05/15||IRIDEX Reports 2014 Fourth Quarter, Year-End Results|
|Record Revenues for the Quarter and the Year
MOUNTAIN VIEW, Calif., March 5, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 3, 2015.
Revenues were $11.8 million in the fourth quarter of 2014, a record for the Company and up 11% from $10.6 million in the 2013 fourth quarter. Revenues for 2014 were $42.8 million, also a record, up 12% from $38.3 million in 2013.
Gross margin for the 2014 ... |
|Primary IR Contact|
Chief Financial Officer and Chief Operating Officer
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.